Classification ![]() |
|
| Compound class | Peptide or derivative |
| Approved drug? | Yes (source: FDA (1993)) |
International Nonproprietary Names ![]() |
|
| INN number | INN |
| 5380 | interferon beta |
Synonyms ![]() |
| Betaferon® |
| Betaseron® |
| Extavia® |
| IFNb1b |
Database Links ![]() |
|
| Specialist databases | |
| IMGT/mAb-DB | 641 |
| Other databases | |
| DrugBank Ligand | DB00068 |
| Search PubMed clinical trials | interferon beta |
| Search PubMed titles | interferon beta |
| Search PubMed titles/abstracts | interferon beta |
| Wikipedia | Interferon_beta_1b |
| Comments |
| Compared to the sequence of endogenous IFN-β, IFN-β1b has a Ser to Cys substitution at position 17, but does not retain the glycosylation site at Asn80. It also lacks the initiating Met. This recombinant peptide is produced in E.coli. |